A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia

Inclusion Criteria: * Patients who were 18 years or older. * Signed informed consent was obtained. * Patients who received at least one inclisiran injection in the identification period. * Patients with at least one diagnosis of ASCVD, ASCVD-RE or FH diagnosis prior to index date. * Patients with at least one low-density lipoprotein cholesterol (LDL-C) measurement of 70 milligrams per deciliter (mg/dL) or greater, within 6 months prior to index date. ASCVD was defined as previous diagnosis of coronary artery disease (CAD), peripheral artery disease (PAD) or cerebrovascular disease (CVD). ASCVD-RE was defined as: no previous diagnosis of ASCVD at any time on the patient chart and they met at least one of the following criteria: * Diagnosis of type II diabetes mellitus (T2DM). * Diagnosis of type I diabetes mellitus (T1DM) of long duration (greater than 20 years). * 10-year risk of 20% or greater by Framingham risk score. Exclusion Criteria: • None.